Author information:
(1)Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; 
Stephane Oudard, Université Paris Descartes, Paris, France; Robert Jones, 
Institute of Cancer Sciences, University of Glasgow, Glasgow; Johann De Bono, 
The Institute of Cancer Research, London, United Kingdom; Eleni Efstathiou, 
University of Athens Medical School, Athens; George Fountzilas, Aristotle 
University of Thessaloniki School of Medicine, Thessaloniki, Greece; Fred Saad, 
University of Montreal Hospital Center, Montreal, Canada; Ronald de Wit, Erasmus 
University Medical Center, Rotterdam, the Netherlands; Felipe Melo Cruz, ABC 
Foundation School of Medicine, Santo André; Flavio Carcano, Hospital de Cancer 
de Barretos, Barretos, Brazil; Albertas Ulys, Institut of Oncology, Vilnius 
University, Vilnius, Lithuania; Neeraj Agarwal, Huntsman Cancer Institute, 
University of Utah, Salt Lake City, UT; David Agus, University of Southern 
California, Los Angeles, CA; Daniel P. Petrylak, Yale University Cancer Center, 
New Haven, CT; Shih-Yuan Lee, Bindu Tejura, Niels Borgstein, Takeda 
Pharmaceuticals International; Iain J. Webb, Millennium: The Takeda Oncology 
Company, Cambridge, MA; Robert Dreicer, Cleveland Clinic, Cleveland, OH; Joaquim 
Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain. 
karim.fizazi@gustaveroussy.fr.
(2)Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif; 
Stephane Oudard, Université Paris Descartes, Paris, France; Robert Jones, 
Institute of Cancer Sciences, University of Glasgow, Glasgow; Johann De Bono, 
The Institute of Cancer Research, London, United Kingdom; Eleni Efstathiou, 
University of Athens Medical School, Athens; George Fountzilas, Aristotle 
University of Thessaloniki School of Medicine, Thessaloniki, Greece; Fred Saad, 
University of Montreal Hospital Center, Montreal, Canada; Ronald de Wit, Erasmus 
University Medical Center, Rotterdam, the Netherlands; Felipe Melo Cruz, ABC 
Foundation School of Medicine, Santo André; Flavio Carcano, Hospital de Cancer 
de Barretos, Barretos, Brazil; Albertas Ulys, Institut of Oncology, Vilnius 
University, Vilnius, Lithuania; Neeraj Agarwal, Huntsman Cancer Institute, 
University of Utah, Salt Lake City, UT; David Agus, University of Southern 
California, Los Angeles, CA; Daniel P. Petrylak, Yale University Cancer Center, 
New Haven, CT; Shih-Yuan Lee, Bindu Tejura, Niels Borgstein, Takeda 
Pharmaceuticals International; Iain J. Webb, Millennium: The Takeda Oncology 
Company, Cambridge, MA; Robert Dreicer, Cleveland Clinic, Cleveland, OH; Joaquim 
Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain.